Neal D. Shore, MD, FACS of Carolina Urologic Research Center discusses how and where chemotherapy fits into treating patients with prostate cancer. This was recorded at the 2017 Genitourinary Cancers Symposium (Annual Meeting GU) in Orlando, Florida.
Author: Editor
Neal D. Shore, MD, FACS of Carolina Urologic Research Center gives his take on which metastatic castration-resistant prostate cancer patients should be treated with chemotherapy at the 2017 Genitourinary Cancers Symposium (Annual Meeting GU) in Orlando, Florida.
Neal D. Shore, MD, FACS of Carolina Urologic Research Center explains how BRCA1 and BRCA2 genetic testing are significantly changing how prostate cancer should be treated. He believes that guidelines are a bit premature, but nonetheless, they are helping with therapy options for patients. This was recorded at the 2017 Genitourinary Cancers Symposium (Annual Meeting GU) in Orlando, Florida.
Wendy S. Harpham, MD, FACP of Presbyterian Hospital of Dallas discusses the medical benefits of finding and nourishing hope, which help patients deal with their uncertainty. She defines hope as a pleasant feeling linked to the belief that the desired outcome can happen. Ultimately, hope is a shared mission, and doctors can help patients by sharing their own hopes for them having the best possible outcome. This was recorded at ASCO’s Cancer Survivorship Symposium: Advancing Care and Research in San Diego, CA.
Wendy S. Harpham, MD, FACP of Presbyterian Hospital of Dallas advises on how to focus on hope for the best clinical outcomes for patients. She believes that hope is a feeling that is based on a belief of a future outcome. Patients are basing their beliefs on what doctors show them, which are stories, impressions, and facts that are based on a reality. If doctors succeed in providing these truths, then hope should naturally occur in patients, and that is the best outcome. This was recorded at ASCO’s Cancer Survivorship Symposium: Advancing Care and Research in San Diego, CA.
Wendy S. Harpham, MD, FACP of Presbyterian Hospital of Dallas explains why there is no one or right approach to survivorship. She states that in order to treat all patients, doctors have to help each patient individually. This was recorded at ASCO’s Cancer Survivorship Symposium: Advancing Care and Research in San Diego, CA.
Mohamad E. Allaf, MD of Johns Hopkins University School of Medicine discusses potential approaches physicians should consider when treating metastatic non-clear cell renal cell carcinoma at the 2017 Genitourinary Cancers Symposium (Annual Meeting GU) in Orlando, Florida.
Marcus Butler, MD, from the Princess Margaret Cancer Centre, Toronto, Canada, discusses data on the efficacy of pembrolizumab treatment in advanced mucosal melanoma, which he presented at the European Cancer Congress of the European Cancer Organisation (ECCO) 2017 in Amsterdam, Netherlands. This type of melanoma develops for unknown reasons unrelated to UV light exposure, and historically has a lower response rate and overall survival (OS) following various treatments. The development of new melanoma treatments, particularly immunotherapy, led Dr Butler to investigate the efficacy of these in mucosal melanoma by combining the results from the KEYNOTE-001 (NCT01295827), KEYNOTE-002 (NCT01704287), and KEYNOTE-006…
Patrick Miqueu, PhD, from the Jules Bordet Institute in Brussels, Belgium, describes a pilot project to improve the collaboration and communication between cancer patient organizations and hospitals, recorded at the European Cancer Congress of the European Cancer Organisation (ECCO) 2017 in Amsterdam, Netherlands. He describes how together with the European Cancer Patient Coalition (ECPC) and Organisation of European Cancer Institutes (OECI), the Jules Bordet Institute aims to develop a minimalist model of fostering collaboration which can be applied in different European countries with existing frameworks. The project focusses on the atmosphere in cancer centers, developing a model which will be…
Lydia Makaroff, PhD, from the European Cancer Patient Coalition, introduces the coalitions new position paper, The Value of Innovation in Oncology, at the European Cancer Congress of the European Cancer Organisation (ECCO) 2017 in Amsterdam, Netherlands. The European Cancer Patient Coalition represents more than 400 cancer patient organizations across Europe. Dr Makaroff describes the new position paper, which contains cost effective and pragmatic recommendations for European institutions and EU member states to ensure cancer patients throughout Europe have access to innovative care, technologies and treatments. The European Cancer Patient Coalition recommends that the assessment of cost effectiveness within Europe should…
Scott Murray, MD, FRCGP, FRCP Edin from the University of Edinburgh, Edinburgh, Scotland, discusses the talk he gave on different features of palliative care at the European Cancer Congress of the European Cancer Organisation (ECCO) 2017 in Amsterdam, Netherlands. He highlights three important aspects. Firstly, palliative care needs should be identified as early as possible, starting at diagnosis, and services should be available within the community. Secondly, an assessment of the patients well-being should be made, including not just physical, but also psychosocial, social and existential issues the patient may be experiencing. Thirdly, a plan should be made together with…
Richard Neal, MB, ChB, PhD, FRCGP, from the Leeds Institute of Health Sciences, Leeds, UK, discusses his talk on reducing diagnostic delay for better cancer outcomes, which he presented at the European Cancer Congress of the European Cancer Organisation (ECCO) 2017 in Amsterdam, Netherlands. He describes that early diagnosis is associated with better cancer outcomes, and suggests that health care systems with a slower diagnosis process can learn from countries with faster diagnosis, resulting in better outcomes. Prof. Neal highlights three ways in which earlier diagnosis can be achieved. Firstly, patients should be encouraged to visit their healthcare practitioner when…
Katsuo Usuda, MD, PhD, from Kanazawa Medical University, Ishikawa, Japan argues that diffusion-weighted magnetic resonance imaging (DWI, MRI) will soon replace PET-CT for lung cancer diagnosis at the European Cancer Congress of the European Cancer Organisation (ECCO) 2017 in Amsterdam, Netherlands. He discusses the benefits of diffusion-weighted MRI, which is not only cheaper than PET-CT, but also does not expose the patient to radiation.
Mohamad E. Allaf, MD of Johns Hopkins University School of Medicine discusses how hopeful he is when it comes to treating non-metastatic renal cell carcinoma patients with adjuvant therapy at the 2017 Genitourinary Cancers Symposium (Annual Meeting GU) in Orlando, Florida.
Mohamad E. Allaf, MD of Johns Hopkins University School of Medicine discusses which non-metastatic renal cell cancer patients should receive adjuvant therapy at the 2017 Genitourinary Cancers Symposium (Annual Meeting GU) in Orlando, Florida.
Matthew I. Milowsky, MD of North Carolina at Chapel Hill School of Medicine discusses how genomics are changing the way bladder cancer subtypes are being treated at the 2017 Genitourinary Cancers Symposium (Annual Meeting GU) in Orlando, Florida.
Matthew I. Milowsky, MD of North Carolina at Chapel Hill School of Medicine discusses how genomics are helping us understand heterogeneity in bladder cancer at the 2017 Genitourinary Cancers Symposium (Annual Meeting GU) in Orlando, Florida.
Matthew I. Milowsky, MD of University of North Carolina at Chapel Hill School of Medicine discusses his presentation, “Urothelial Carcinoma: Year in Review,” which was presented at the 2017 Genitourinary Cancers Symposium (Annual Meeting GU) in Orlando, Florida.
Jeffrey M. Holzbeierlein, MD of University of Kansas Hospital gives his take on the most promising data coming out of the 2017 Genitourinary Cancers Symposium (Annual Meeting GU) in Orlando, Florida.
Jeffrey M. Holzbeierlein, MD of University of Kansas Hospital discusses presentations he found interesting at the symposium, specifically David J. McConkey’s keynote lecture “Urothelial Carcinoma: Emerging Impact of Genomics on the Clinical Management of Bladder Cancer,” which was presented at the 2017 Genitourinary Cancers Symposium (Annual Meeting GU) in Orlando, Florida.
Jeffrey M. Holzbeierlein, MD of University of Kansas Hospital gives an overview of the upcoming treatment trends for genitourinary cancers in 2017, which were discussed at the Genitourinary Cancers Symposium (Annual Meeting GU) in Orlando, Florida.
Jeffrey M. Holzbeierlein, MD of University of Kansas Hospital discusses his presentation, “Orphan Cancers with Opportunities for Improved Treatment (ARS)” and how his data will affect clinicians in the same field at the 2017 Genitourinary Cancers Symposium (Annual Meeting GU) in Orlando, Florida.
Jeffrey M. Holzbeierlein, MD of University of Kansas Hospital gives an overview of his presentation “Orphan Cancers with Opportunities for Improved Treatment (ARS),” which was presented at the 2017 Genitourinary Cancers Symposium (Annual Meeting GU) in Orlando, Florida.
James Brugarolas, MD of UT Southwestern Medical Center gives an overview of the new kidney cancer research that was presented at the 2017 Genitourinary Cancers Symposium (Annual Meeting GU) in Orlando, Florida.
James Brugarolas, MD of UT Southwestern Medical Center discusses the use of targeted therapies in treating non-clear cell renal cell carcinoma at the 2017 Genitourinary Cancers Symposium (Annual Meeting GU) in Orlando, Florida.
Freddie C. Hamdy, MD of University of Oxford gives an overview of the new research that was discussed regarding prostate cancer at the 2017 Genitourinary Cancers Symposium (Annual Meeting GU) in Orlando, Florida.
Freddie C. Hamdy, MD of University of Oxford gives his take on which choice would warrant over the others when it comes to their difference in side effects for patients with metastatic prostate cancer at the 2017 Genitourinary Cancers Symposium (Annual Meeting GU) in Orlando, Florida.
Freddie C. Hamdy, MD of University of Oxford discusses the how surgery, radiation, and active surveillance arms of the ProtecT study differ in terms of overall survival and metastasis free patients at the 2017 Genitourinary Cancers Symposium (Annual Meeting GU) in Orlando, Florida.
Freddie C. Hamdy, MD of University of Oxford discusses the results of the ProtecT study, which was presented at the 2017 Genitourinary Cancers Symposium (Annual Meeting GU) in Orlando, Florida.
Freddie C. Hamdy, MD of University of Oxford gives an overview of how the ProtecT study was designed for prostate cancer research at 2017 Genitourinary Cancers Symposium (Annual Meeting GU) in Orlando, Florida.
Mohamad E. Allaf, MD of Johns Hopkins University School of Medicine discusses how immunotherapies are being integrated into treatment for renal cell carcinoma at the 2017 Genitourinary Cancers Symposium (Annual Meeting GU) in Orlando, Florida.
Eric Jonasch, MD of MD Anderson Cancer Center gives an overview of how targeted therapies are being used in treating non-clear cell renal cell carcinoma at the 2017 Genitourinary Cancers Symposium (Annual Meeting GU) in Orlando, Florida.
Eric Jonasch, MD of MD Anderson Cancer Center discusses what approaches should physicians consider when treating patients with metastatic non-clear renal cell carcinoma at the 2017 Genitourinary Cancers Symposium (Annual Meeting GU) in Orlando, Florida.
Eric Jonasch, MD of MD Anderson Cancer Center discusses the use of adjuvant therapy to treat patients with non-metastatic renal cell carcinoma at the 2017 Genitourinary Cancers Symposium (Annual Meeting GU) in Orlando, Florida.
James Brugarolas, MD of UT Southwestern Medical Center gives his take on which non-metastatic renal cell cancer patients should receive adjuvant therapy at the 2017 Genitourinary Cancers Symposium (Annual Meeting GU) in Orlando, Florida.
In this presentation from Lymphoma & Myeloma 2016, Dr. Steven Coutre provides an update on approved tyrosine-kinase inhibitors (TKIs) and their use in clinical practice for the treatment of chronic lymphocytic leukemia (CLL). Click to Earn CME Credit: http://bit.ly/2lDPthL © 2016 Imedex, LLC.
In this presentation from Lymphoma & Myeloma 2016, Dr. Richard R. Furman discusses the recent FDA approval of venetoclax for the treatment of chronic lymphocytic leukemia (CLL). Click to Earn CME Credit: http://bit.ly/2lDPthL © 2016 Imedex, LLC.
In this presentation from Lymphoma & Myeloma 2016, Dr. Bruce D. Cheson discusses the role of chemotherapy in the management of chronic lymphocytic leukemia (CLL). Click to Earn CME Credit: http://bit.ly/2lDPthL © 2016 Imedex, LLC.
In this presentation from Lymphoma & Myeloma 2016, Dr. Susan Slager discusses the epidemiology of chronic lymphocytic leukemia (CLL), and assess what we know about risk. Click to Earn CME Credit: http://bit.ly/2lDPthL © 2016 Imedex, LLC.
In this presentation from Lymphoma & Myeloma 2016, Dr. Y. Lynn Wang discusses ibrutinib resistance-mechanisms in the treatment of chronic lymphocytic leukemia (CLL). Click to Earn CME Credit: http://bit.ly/2lDPthL © 2016 Imedex, LLC.
In this presentation from Lymphoma & Myeloma 2016, Dr. Jennifer R. Brown discusses the BCR signaling pathway in the treatment of chronic lymphocytic leukemia (CLL). Click to Earn CME Credit: http://bit.ly/2lDPthL © 2016 Imedex, LLC.
In this presentation from Lymphoma & Myeloma 2016, Dr. Paul G. Richardson examines how to make sense of the many options available for the treatment of relapsed myeloma. Click to Earn CME Credit: http://bit.ly/2mFGsEq © 2016 Imedex, LLC.
In this presentation from Lymphoma & Myeloma 2016, Dr. Tomer M. Mark discusses monoclonal antibodies in the therapeutic treatment of myeloma. Click to Earn CME Credit: http://bit.ly/2mFGsEq © 2016 Imedex, LLC.
In this presentation from Lymphoma & Myeloma 2016, Dr. Adriana C. Rossi discusses whether second- and third-line agents should be used upfront in combination for myeloma patients. Click to Earn CME Credit: http://bit.ly/2mFGsEq © 2016 Imedex, LLC.
This Key Insights activity features conference chair Kathy S. Albain and Dr. Eric P. Winer discussing highlights from the 14th Annual Best of San Antonio – Breast Cancer: Bench to Bedside. Earn CME credit for this activity at the following location: http://elc.imedex.com/ELC/Activity-Overview.aspx?activityid=7244&specialty=Oncology © 2017 Imedex, LLC.
David J. McConkey, PhD of Johns Hopkins Greenberg Bladder Cancer Institute gives his take on what specific drugs have potential in treating bladder cancer at the 2017 Genitourinary Cancers Symposium (Annual Meeting GU) in Orlando Florida.
David J. McConkey, PhD of Johns Hopkins Greensberg Bladder Cancer Institute gives his opinion on what physicians need to know about the progress being made in treating bladder cancer with checkpoint inhibitors at the 2017 Genitourinary Cancers Symposium (Annual Meeting GU) in Orlando, Florida.
David J. McConkey, PhD of Johns Hopkins Greensberg Bladder Cancer Institute discusses whether or not non-invasive imaging will be ready in the future, and what methods should oncologists use to stage and monitor metastatic bladder cancer at the 2017 Genitourinary Cancers Symposium (Annual Meeting GU) in Orlando, Florida.
David J. McConkey of Johns Hopkins Greensberg Bladder Cancer Institute explains why some bladder cancer subtypes respond to immunotherapy and others do not at the 2017 Genitourinary Cancers Symposium (Annual Meeting GU) in Orlando, Florida.
David J. McConkey, PhD of Johns Hopkins Greensberg Bladder Cancer Institute discusses genomics and how they change treatment for bladder cancer subtypes at the 2017 Genitourinary Cancers Symposium (Annual Meeting GU) in Orlando, Florida.